Start Codon closes a £15m venture fund to back life science and healthcare start-ups
Novartis International and Cambridge Innovation Capital participated in the £15m fund.
Start Codon operates as a business accelerator focused on life science and healthcare start-ups based in Cambridge. The organisation provides seed funding, mentoring, and lab facilities to translate early-stage research into commercial enterprises.
Cambridge-based life science and healthcare accelerator Start Codon has closed its first venture fund at £15m. The capital will be deployed to back early-stage ventures through seed funding, business support, and access to workspace and laboratory facilities. Backers in the vehicle include Novartis International and Cambridge Innovation Capital, with the former also offering mentorship and commercial partnership opportunities to participating founders.
The organisation plans to support up to 50 companies over the next five years. Having already showcased its inaugural cohort and enrolled a second group of ventures, Start Codon continues to scout for innovative health technologies.
Investor perspective
"This venture fund will provide start-ups with the opportunity to kick start their development and will bring novel and innovative ideas to commercialisation. We are delighted to have supported Start Codon since its inception and are excited to see it act as an important facilitator in creating success in Cambridge and throughout the UK."
Michael Anstey
Partner, Cambridge Innovation Capital
Use of funds
- 01Scale operations
Investors
About the company
Start Codon
Start Codon accelerates life science and healthcare start-ups through funding and expert guidance.